RxDoctor Payments Data

Sameer Chawla, MD

Urology · Raleigh, NCNPI 1679511661

Payments from drug & device makers

$4,356in general payments, 2019–2025

Across 84 payments — averaging $51.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Pfizer$258
  • Johnson & Johnson$257
  • Antares Pharma, Inc.$206
  • Sumitomo Pharma America, Inc.$179
  • Urogen Pharma, Inc.$174
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$1,50034%
  • Travel & lodging$3167%
  • Food & beverage$2,35154%
  • Education$1894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,356 in reported general payments places this provider in the 60th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$154,154
Medicare patients
446
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron99$73,133
GemtesaVibegron20$17,903
Tamsulosin Hcl636$10,250
Finasteride256$4,380
Testosterone11$3,626
Testosterone Cypionate56$3,063
Alfuzosin Hcl ErAlfuzosin Hcl69$2,889
Estradiol20$1,447
Solifenacin Succinate17$724
Trospium Chloride17$717
Doxazosin Mesylate14$422
Dutasteride18$392
Celecoxib27$346
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst85$248
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav27$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$137$73,13399 claims
Sumitomo Pharma America, Inc.Gemtesa$179$17,90320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →